{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ivanova A"],"funding":["Keenan Chair in Surgery","Gratitude 10","Ontario Graduate Scholarship","Brainchild","Oxford University Press","Calum Macbeth Fund","the Early Research Award from the Province of Ontario","Meagan’s Walk","Canadian Institutes of Health Research"],"pagination":["e186703"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12487684"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(17)"],"pubmed_abstract":["More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma. In vitro treatment of temozolomide-resistant glioblastoma cells with lomitapide resulted in decreased intracellular ubiquinone levels and sensitized cells to temozolomide-induced ferroptosis. Concomitant treatment with lomitapide and temozolomide (TMZ) prolonged survival and delayed tumor recurrence in a mouse glioblastoma m"],"journal":["JCI insight"],"pubmed_title":["Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma."],"pmcid":["PMC12487684"],"funding_grant_id":["VPiX","Keenan Chair in Surgery","royalties","Brainchild","Calum Macbeth Fund","Synaptive","OGS","the Early Research Award from the Province of Ontario","Meagan’s Walk","CIHR-OG-341329","philanthropic funds"],"pubmed_authors":["Ivanova A","Wu M","Das S","Flick R","Wilson TM","Ghannad-Zadeh K","Tse E"],"additional_accession":[]},"is_claimable":false,"name":"Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma.","description":"More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma. In vitro treatment of temozolomide-resistant glioblastoma cells with lomitapide resulted in decreased intracellular ubiquinone levels and sensitized cells to temozolomide-induced ferroptosis. Concomitant treatment with lomitapide and temozolomide (TMZ) prolonged survival and delayed tumor recurrence in a mouse glioblastoma m","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-04T01:23:42.21Z","creation":"2026-05-03T03:13:57.749Z"},"accession":"S-EPMC12487684","cross_references":{"pubmed":["40923320"],"doi":["10.1172/jci.insight.186703"]}}